LATAM Pemetrexed Market Size & Outlook, 2025-2033


LATAM Pemetrexed Market Insights

  • Based on Reed Intelligence findings, the LATAM Pemetrexed Market size reached USD 123.08 Million in 2024 and is expected to grow to USD 138.86 Million by 2033.
  • During 2026–2033, the market is forecasted to advance at a CAGR of 1.36%.
  • Malignant Pleural Mesothelioma represented the largest share of the By Application market in terms of size in 2024.
  • Among the By Application segments, Non-Squamous NSCLC is forecasted to achieve the highest growth and remain the most lucrative through the forecast period.

Other Key Findings


  • LATAM represented 5.26% of the global Pemetrexed Market size in 2024.
  • By 2033, United States is estimated to hold the largest position in the global market in terms of size.
  • Chile is estimated to remain the fastest-growing market in LATAM, advancing to USD 11.17 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 123.08 Million
Market Size In 2033 USD 138.86 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.36% (2025-2033)
Segmnetation Covered
LATAM
  1. Brazil
  2. Mexico
  3. Argentina
  4. Colombia
  5. Chile
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends